Optimised coding sequence and promoter

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9393323
SERIAL NO

13382953

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ST. JUDE CHILDREN'S RESEARCH HOSPITAL;THROMBOSIS RESEARCH INSTITUTE;UCL BUSINESS PLC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Davidoff, Andrew Memphis, US 13 134
Gray, John Memphis, US 68 2309
McVey, John Beaconsfield, GB 10 403
Nathwani, Amit London, GB 36 197
Thrasher, Adrian London, GB 7 107
Tuddenham, Edward London, GB 16 168
Ward, Natalie London, GB 4 100

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 19, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00